参考文献
1 Van der Kwast TH，Schalken J，Ruizevelt de Winter JA，et al.Androgen receptors in endocrine-therpy-resistant human prostate cancer.Int JCancer，1991，48：189-193.
Ruizevelt de Winter JA，Janssen PJA，Sleddens HMEB，et al.Androgen receptor status in localized and locally progressive hormone refractory huˉman prostate cancer.Am J Pathol，1994，144：735-746.
Hobisch A，Culig Z，Radmayr C，et al.Distant metastases from progstatic carcinoma express androgen receptor protein.Cacner Res，1995，55：3068-3072.
Hobisch A，Culig Z，Radmayr C，et al.Androgen receptor status of lymph node metastases from protstate cancer.Prostate，1996，28：129-135.
5 Radmayr C，Culig Z，Hobisch A，et al.Analysis of a mutant androgen reˉceptor offers a treatment modality in a patient with partial androgen insenˉsitivity syndrome.Eur Urol，1998，33：222-226.
6 Marcelli M，Irrmann M，Mariani S，et al.Androgen receptor mutation in prostate cancer.Cancer Res，2000，60：944-949.
7 Veldscholte J，Ris-Stalpers C，Kuiper GGJM，et al.A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells afˉfects steroid binding characteristics and response to anti-androgens.Biochem Biophys Res Commun，1990，17：534-540.
8 Taplin ME，Bubley GJ，Ko YJ，et al.Selection for androgen receptor mutaˉtions in prostate cancers treated with androgen antagonist.Cancer Res，1999，59：2511-2515.
9 Gaddipati JP，McLeod DG，Heidenberg HB，et al.Frequent detection of codon877mutation in the androgen receptor gene in advanced prostate cancers.Cancer Res，1994，54：2861-2866.
10 Bubley G，FentonM，Fertig A，et al.The hormonal sensitivity of androgen receptor（AR）mutations derived from human tumors.Cancer Res（Proˉceedings），1996，37：246.
11 Zhao XY，Malloy PJ，Krishnan AV，et al.Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor.Nat Med，2000，6：703-706.
12 Culig Z，Hobisch A，Cronauer MV，et al.Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-1，keratinocyte growth factor，and epidermal growth factor.Cancer Res，1994，54：5474-5478.
13 Hobisch A，Eder IE，Iris E，et al.Interleukin-6regulates actitivation of the androgen receptor.Cancer Res，1998，58：4640-4645.
14 Sadar MD.Androgen-independent induction of prostate specific antigen gene expression via across-talk between the androgen receptor and proˉtein kinase A signal transduction pathways.J Biol Chem，1999，274（12）：7777-7783.
15 Nazareth LV，Weigel NL.Activation of the juman androgen receptorthrough a protein kinase A signaling pathway.J Biol Chem，1996，271（33）：19900-19907.
16 Craft NA，Shostak Y，Carey M，et al.A mechanism for hormone-indeˉpendent prostate cancer through modulation of androgen receptor signalˉing by the Her-2/neu tyrosine kinase.Nature Med，1999，5（3）：280-285.
17 Craft NA，Shostak Y，Carey M，et al.A mechanism for hormone-indeˉpendent prostate cancer through modulation of androgen receptor signalˉing by the Her-2/neu tyrosine kinase.Nature Med，1999，5（3）：280-285.
18 Signoretti S，Montironi R，Manola J，et al.Her-2-neu expression toˉward androgen independence in human prostate cancer.J Natl Cancer Inˉst，2000，92：1918-1925.
19 Culig Z，Hobisch A，Bartisch G，et al.Androgen receptor-an update of mechanisms of action in prostate cancer.Urol Res，2000，28：211-219
20 Nessler-Menardi C，Jotova I，Culig Z，et al.Expression of androgen reˉceptor coregulatory proteins in prostate cancer and stromal-cellculture models.Prostate，2000，45：124-131.
21 Hellawell GO，Ferguson DJ，Brewster SF，et al.Chemosensitizationof huˉman prostate cancer using antisense agents tareting the type1insulin-like growth factor receptor.BJU Int，2003，91（3）：271-277.
22 Weeraratna AT，Arnold JT，George D，et al.Rational basis for trkinhibiˉtion therapy for prostate cancer.Prostate，2000，45：140-148.
23 Scher HI，Sarkis A，Reuter V，et al.Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor in the progression of prostatic neoplasms.Clin Cancer Res，1995，1：545-550.
24 Sirotnak FM，She Y，Lee F，et al.Studies with CWR22xenografts innude mice suggest that ZD1839may have a role in the treatment of both anˉdrogen-dependent and androgen-independent human prostate cancer.Clin Cancer Res，2002，8（12）：3870-3876.
25 Colombel M，Symmans F，Gil S，et al.Detection of the apoptosis-supˉpressing oncoprotein bcl-2in hormone-refractory human prostate canˉcer.Am J Pathol，1993，143（2）：390-400.
26 Raffo AJ，Perlman H，Chen MW，et al.Overexpression of bcl-2resisˉtance to androgen depletion in vivo.Cancer Res，1995，55（19）：4438-4445.
27 Kelly WK，Scher HI.Prostate specific antigen decline after antiandrogen withdrawal：The flutamide withdrawal syndrome.J Urol，1993，149（3）：607-609.
28 Oefelein MG，Ricchiuti VS，Conrad PW，et al.Clinical predictors of anˉdrogen-independent prosate cancer and survival in the prostate-speˉcific antigen era.Urology，2002，60（1）：120-124.
29 Scher HI，Kelly WK.Flutamide withdrawal syndrome：Its impact on cliniˉcal trials in hormone-refractory prostate cancer.J Clin Oncol，1993，11（8）：1566-1572.
30 OH WK.Secondary hormonal therapies in the treatment of prostate canˉ cer.Urology，2002，60（3Suppl1）：87-92；discussion93.
31 Peehl DM，Seto E，Feldman D，et al.Rationale for combination ketoconaˉzole/vitamin D treatment of prostate cancer.Urology，2001，58（2Suppl1）：123-126.
32 Saika T，Kusaka N，Tsushima T，et al.Treatment of androgen-indepenˉdent prostate cancer with dexamethasone：a prostpective study in stage D2patients.Int J Urol，2001，8（6）：290-294.
33 OH WK，Kantoff PW.Management of hormone refractory prostate canˉcer.Current standards and future prospects.J Urol，1998，160（4）：1220-1229.
34 Millikan R，Thall PF，Lee SJ，et al.Randomized，multicenter，phaseⅡtrial of two multicomponent regimens in androgen-independent prostate cancer.J Clin Oncol，2003，21（5）：878-883.
35 Beer TM，Bubalo JS.Effects of docetaxel on pain due to metastatic anˉdrogen-independent prostate cancer.Curr Urol Rep，2002，3（3）：232-238.
36 Fox WD，Higgins B，Maiese KM，et al.Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer.Clin Cancer Res，2002，8（10）：3226-3231.
37 Seidman AD，Scher HI，Petrylak D，et al.Estramustine and vinblastine：Use of prostate specific antigen as a clinical trial end point forhormone refractory prostatic cancer.J Urol，1992，147（3Pt2）：931-934.
38 Attivissimo LA，Fetten JV，Kreis W.Symptomatic improvement associated with combined estramustine and vinblastine chemotherapy for metastatic prostate cancer.Am J Clin Oncol，1996，19（6）：581-583.
39 Park DS，Vassilopoulou-Sellin R，Tu S.Estramustine-related hypocalˉcemia in patients with prostate carcinoma and osteoblastic metastases.Urology，2001，58（1）：105.
40 Myers C，Cooper M，Stein C，et al.Suramin：A novel growth factor antagˉonist with activity in hormone-refractory metastatic prostate cancer.J Clin Oncol，1992，10：881.
41 Eisenberger MA，Sinibaldi VJ，Reyno LM，et al.Phase I and clinical eˉvaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer.J Clin Oncol，1995，13（9）：2174-2186.
42 Bonham MJ，Galkin A，Montgomery B，et al.Effects of the herbal extract PC-SPES on microtubule dynamics and paclitaxel-mediated prostatetumor growth inhibition.J Natl Cancer Inst，2002，94（21）：1641-1647.